ARV-102: Oral PROTAC LRRK2 degrader. 

Feb 11, 2025 - Initiated a Phase 1 trial with ARV-102 in patients with Parkinson’s disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer’s Disease/Parkinson’s Disease congress. Full annoucement: https://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-fourth-quarter-and-full-year-2024-financial